{"id":679,"date":"2024-05-31T14:43:03","date_gmt":"2024-05-31T12:43:03","guid":{"rendered":"https:\/\/hmi-test.ezenit.link\/?p=679"},"modified":"2024-07-17T16:09:31","modified_gmt":"2024-07-17T14:09:31","slug":"dra-judit-becker","status":"publish","type":"post","link":"https:\/\/hmi-test.ezenit.link\/en\/dra-judit-becker\/","title":{"rendered":"HM Hospitales\u2019 Research Foundation helped nearly 1,000 patients in more than 300 clinic trials in 2023"},"content":{"rendered":"<style>.elementor-679 .elementor-element.elementor-element-d444160{--display:flex;}.elementor-widget-text-editor{font-family:var( --e-global-typography-text-font-family ), Sans-serif;font-weight:var( --e-global-typography-text-font-weight );color:var( --e-global-color-text );}.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:var( --e-global-color-primary );}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap, .elementor-widget-text-editor.elementor-drop-cap-view-default .elementor-drop-cap{color:var( --e-global-color-primary );border-color:var( --e-global-color-primary );}<\/style>\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"679\" class=\"elementor elementor-679\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d444160 e-flex e-con-boxed e-con e-parent\" data-id=\"d444160\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cede818 elementor-widget elementor-widget-text-editor\" data-id=\"cede818\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u2022 The Fundaci\u00f3n HM (HM Foundation) published 223 publications last year and has\u00a0achieved the accumulated impact rates and higher average impact in its history.<\/strong><\/p><p><strong>\u2022 The HM Foundation Vaccine Unit is consolidated as one of the most active in Europe with substantial growth in new projects.<\/strong><\/p><p><strong>\u2022 The science of health data and artificial intelligence are revealed as areas of strategic expansion as endorsed the agreement reached with Savana to lead digital transformation within private health.<\/strong><\/p><p><strong>\u2022 The third edition of the Dr. Juan Abarca International Medical Sciences Award recognised the work of Professor Douglas A. Melton for his disruptive development in the cure of type 1 diabetes.<\/strong><\/p><p>The Fundaci\u00f3n de Investigaci\u00f3n HM Hospitales (FIHM) has registered one more year\u00a0record figures that consolidate it as one of the Spanish private institutions of reference\u00a0in the field of clinical research and scientific knowledge. During 2023, the Foundation\u00a0FiHM has carried out more than 300 clinical trials amongst 1,000 patients, and around\u00a070% were oncological with the total participation of 403 patients.<\/p><p>Oncological tests in early stages represent 28% and in this section the unit of clinical\u00a0trials in phase I Start &#8211; HM CIOCC, led by Dr. Emiliano Calvo, has a vital importance.<\/p><p>Dr. Juan Abarca Cid\u00f3n, president of HM Hospitales, emphasizes that, \u201cyear after year\u00a0the data of the HM Foundation&#8217;s research activity improves, keeping the focus on the\u00a0priority objective set 20 years ago of setting a platform for translational medicine. In\u00a0other words, the one that goes from the laboratory to the direct application on patients.\u00a0In addition, I am deeply proud that our Research Foundation, only with the publications\u00a0of HM Sanchinarro, is in the Top 30 of Spanish health institutions in the world ranking\u00a0Scimago, ahead of many great public hospitals, which is an incredible sign of the power\u00a0of our researchers.\u201d<\/p><p>Another very prominent aspect of the figures achieved by FiHM is focused on the\u00a0spread of scientific activity, which has managed to succeed previous records, and whichis an indisputable symptom of experienced growth as a reference within the Spanish\u00a0health system. In that sense, there have been 223 publications, more than half of them in\u00a0Q1 \u201374 in Oncology, 31 in neurosciences and 21 in cardiology &#8211; which have reached an\u00a0accumulated impact index of 2,444.01 and an impressive average impact rate of 10.96.\u00a0\u201cThese records are an indication of the increase in quality of our scientific productions.\u00a0Our clinical researchers are able to carry out research with the very high scientific impact in all areas, achieving an average impact index of almost eleven points, which proves the excellence of the publications,\u201d says Dr. Jos\u00e9 Mar\u00eda Castellano, scientific director of the FiHM.<\/p><p>Good examples of the trials and publications made in 2023 have been the publication of\u00a0the results of a clinical trial in the magazine &#8216;Science Advances&#8217;, and whose main authors have been the researchers of the Neuroscience Integral Center for HM CINAC,\u00a0where it is demonstrated for the first time the viability and safety of the temporary opening of the blood cell barrier through low intensity ultrasound (LIFU) in relevant regions for patients with Parkinson&#8217;s disease.<\/p><p><b>Vaccines and data science<\/b><\/p><p>2023 has also meant the international consolidation of the vaccine research unit led by\u00a0Dr. Silvina Natalini, which coordinates several international clinical trials. She started\u00a0clinical trials in eight centers of the HM hospitales group and published in 2023 scientific journals of the impact of \u2018The New England Journal of Medicine\u2019.<\/p><p>In addition to the good results in the most &#8220;classical&#8221; clinical research, the FiHM has\u00a0been leading the digital transformation in this sector within the science of health data.\u00a0Good example of this are the chairs around the health of women, the records of child\u00a0obesity and cardiovascular risk that will continue to give results during the next year.\u00a0Along these lines, the FiHM has partnered with Savana, the Spanish leader in the development of health data science platforms to integrate artificial intelligence in the research center with real life data thanks to the use of the Savana Platform, consolidating\u00a0as such the group as leader in clinical research based on health data. \u201cThe final aim is\u00a0through very precise analysis of clinical, analytical data, image, prescription and pathological anatomy refine diagnoses and treatments to our patients, so we can always provide the best health care,\u201d says Dr. Castellano.<\/p><p><b>Third edition of \u201cABARCA PRIZE\u201d<\/b><\/p><p>2023 has been the year of celebration of the third edition of the Dr. Juan Abarca International Prize &#8216;Abarca Prize&#8217;, which was awarded to Prof. Douglas A. Melton, for its disruptive developments in the cure of type 1 diabetes.\u00a0<\/p><p>Worth 100,000 euros, \u2018Abarca Prize\u2019 is in recognition of the figure of Dr. Juan Abarca\u00a0Campal, founder of the HM Hospitales Group together with Dr. Carmen Cid\u00f3n Tamargo, and to all its values when developing a personalized medicine. In addition, this\u00a0award has already been consolidated as the most important award of our country for therecognition of research in translational medicine, and in this edition it has had the support of SM King Felipe VI.\u00a0<\/p><p>Finally, the FiHM has an intense solidarity activity embodied by the multiple care projects of the HM Nens Social Foundation, also in the area of pediatric oncology and numerous agreements with the associative fabric to sponsor and collaborate in diagnostic\u00a0and social coverage initiatives of diverse nature.<\/p><p>The results of the FiHM are, together with teaching, the main vision of patient-oriented\u00a0medicine practiced by doctors and researchers of the HM Hospitales.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u2022 The Fundaci\u00f3n HM (HM Foundation) published 223 publications last year and has\u00a0achieved the accumulated impact rates and higher average impact in its history. The HM Foundation Vaccine Unit is consolidated as one of the most active in Europe with substantial growth in new projects.<\/p>\n","protected":false},"author":5,"featured_media":2798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,17,12],"tags":[],"class_list":["post-679","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-category-1","category-ginecology"],"_links":{"self":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/comments?post=679"}],"version-history":[{"count":31,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/679\/revisions"}],"predecessor-version":[{"id":3584,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/posts\/679\/revisions\/3584"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/media\/2798"}],"wp:attachment":[{"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/media?parent=679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/categories?post=679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hmi-test.ezenit.link\/en\/wp-json\/wp\/v2\/tags?post=679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}